

**Press release**  
**February 08, 2021**

## **US patent application 14/399,820 relating to uTREAT® is accepted for grant**

**The United States Patent and Trademark Office has issued a notice of allowance confirming that the United States Patent Application no. 14/399,820 regarding 177-Lu Labeled peptide conjugate for site specific uPAR-targeting will be granted. The patent will expire May 2033.**

This patent application relates to Curasight's therapeutic technology uTREAT® and uses thereof. More specifically the invention relates to human uPAR targeted radionuclide therapy, which enables local irradiation of cancer with almost no irradiation of healthy tissue. The Patent Offices of Europe, Japan, China and Hong Kong have previously granted the patent. Together with uTRACE® the combination is known as uPAR Theranostics – the combination of **therapy** and **diagnostics**.

*“The validation of this US patent application has now been officially confirmed by the US Patent Office. For Curasight the addition of the US is a major milestone in the development of uTREAT® as a therapeutic option in cancer. Together with the already granted patent for uTRACE®, this is of paramount importance for our strategy into the North American market”* says CEO Ulrich Krasilnikoff.

**For more information regarding Curasight, please contact:**

Ulrich Krasilnikoff, CEO  
Phone: +45 22 83 01 60  
E-mail: [uk@curasight.com](mailto:uk@curasight.com)  
[www.curasight.com](http://www.curasight.com)

This information is such information that Curasight A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person, for publication on 8 February, 2021.

---

**Curasight** is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.